Which papillary thyroid microcarcinoma should be treated as "true cancer" and which as "precancer"?

Krzysztof Kaliszewski, Dorota Diakowska, Beata Wojtczak, Zdzisław Forkasiewicz, Dominika Pupka, Łukasz Nowak, Jerzy Rudnicki, Krzysztof Kaliszewski, Dorota Diakowska, Beata Wojtczak, Zdzisław Forkasiewicz, Dominika Pupka, Łukasz Nowak, Jerzy Rudnicki

Abstract

Background: Papillary thyroid microcarcinoma (PTMC) generally is a cancer with excellent prognosis, but the term "cancer" sounds severe and harsh, which can elicit emotional and physical responses from patients. To eliminate the word "cancer," the term noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced. However, not all PTMCs can be classified as NIFTP. Sometimes, very aggressive PTMC cases might be observed. Some authors suggest that one of the risk factors for poor prognosis is lymph node metastasis. The aim of the study was to evaluate some clinicopathological features of PTMC as the risk factors for lymph node metastasis.

Material and methods: We performed a retrospective chart review and selected 177 patients with PTMC. To analyze the cases with potentially aggressive behavior, we enrolled PTMC patients with lymph node metastases (pN1, central, and/or lateral) and evaluated some of their clinicopathological features.

Results: The logistic regression analysis results demonstrated significantly higher rates of multifocal or bilateral tumor occurrence in the PTMC patients with pN1 than in the patients with pN0 (P < 0.0001 for both). In addition, the occurrence of thyroid tumors with sizes above 0.5 cm was a significant risk factor for lymph node metastasis (P < 0.0001). The results of the ROC analyses showed that the presence of multifocal or bilateral tumors and tumor sizes above 0.5 cm were significant predictors of lymph node metastasis (P < 0.0001 for all).

Conclusions: Multifocal and bilateral PTMC tumors with diameters above 0.5 cm should be treated aggressively as "true cancer" and might benefit from lymph node dissection. Unifocal PTMC tumors with diameters equal to or below 0.5 cm may be treated less aggressively.

Keywords: Aggressiveness; Metastasis; Papillary thyroid microcarcinoma.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Relationship between lymph node metastasis and the probability of disease-free survival of PTMC patients
Fig. 2
Fig. 2
Comparison of receiver operating curves (ROC) for the presence of multifocal or bilateral tumors or tumor size above 0.5 cm. The performance of a marker unable to discriminate between pN0 and pN1 patients, whose area under the ROC curve (AUC) is equal to 0.5 was marked with a constant line

References

    1. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer. 1989;63:908–911. doi: 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>;2-I.
    1. Kaliszewski K, Strutyńska-Karpińska M, Zubkiewicz-Kucharska A, et al. Should the prevalence of incidental thyroid cancer determine the extent of surgery in multinodular goiter? PLoS One. 2016;11:e0168654. doi: 10.1371/journal.pone.0168654.
    1. Lewiński A, Adamczewski Z. Papillary thyroid carcinoma: a cancer with an extremely diverse genetic background and prognosis. Pol Arch Intern Med. 2017;127:388–389. doi: 10.20452/pamw.4058.
    1. Nickel B, Brito JP, Moynihan R, Barratt A, Jordan S, McCaffery K. Patients’ experiences of diagnosis and management of papillary thyroid microcarcinoma: a qualitative study. BMC Cancer. 2018;18:242. doi: 10.1186/s12885-018-4152-9.
    1. Hong YR, Yan CX, Mo GQ, et al. Conventional US, elastography, and contrast enhanced US features of papillary thyroid microcarcinoma predict central compartment lymph node metastases. Sci Rep. 2015;5:7748. doi: 10.1038/srep07748.
    1. Choi JB, Lee WK, Lee SG, et al. Long-term oncologic outcomes of papillary thyroid microcarcinoma according to the presence of clinically apparent lymph node metastasis: a large retrospective analysis of 5,348 patients. Cancer Manag Res. 2018;10:2883–2891. doi: 10.2147/CMAR.S173853.
    1. Kim JY, Jung EJ, Park T, et al. Impact of tumor size on subclinical central lymph node metastasis in papillary thyroid microcarcinoma depends on age. World J Surg Oncol. 2015;13:88. doi: 10.1186/s12957-015-0478-9.
    1. Jiang W, Wei HY, Zhang HY, Zhuo QL. Value of contrast-enhanced ultrasound combined with elastography in evaluating cervical lymph node metastasis in papillary thyroid carcinoma. World J Clin Casus. 2019;7:49–57. doi: 10.12998/wjcc.v7.i1.49.
    1. Wada N, Duh QY, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237:399–407.
    1. Noguchi S, Yamashita H, Uchino S, Watanabe S. Papillary microcarcinoma. World J Surg. 2008;32:747–753. doi: 10.1007/s00268-007-9453-0.
    1. Ito Y, Tomoda C, Uruno T, et al. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg. 2006;30:91–99. doi: 10.1007/s00268-005-0113-y.
    1. Liu LS, Liang J, Li JH, et al. The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a meta-analysis. Eur Arch Otorhinolaryngol. 2017;274:1327–1338. doi: 10.1007/s00405-016-4302-0.
    1. Sakorafas GH, Sampanis D, Safioleas M. Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties. Surg Oncol. 2010;19:e57–e70. doi: 10.1016/j.suronc.2009.04.002.
    1. White ML, Doherty GM. Level VI lymph node dissection for papillary thyroid cancer. Minerva Chir. 2007;62:383–393.
    1. Sadowski BM, Snyder SK, Lairmore TC. Routine bilateral central lymph node clearance for papillary thyroid cancer. Surgery. 2009;146:696–703. doi: 10.1016/j.surg.2009.06.046.
    1. Moo TA, McGill J, Allendorf J, Lee J, Fahey T, Zarnegar R. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg. 2010;34:1187–1191. doi: 10.1007/s00268-010-0418-3.
    1. Chang YW, Kim HS, Kim HY, Lee JB, Bae JW, Son GS. Should central lymph node dissection be considered for all papillary thyroid microcarcinoma? Asian J Surg. 2016;39:197–201. doi: 10.1016/j.asjsur.2015.02.006.
    1. Zhi J, Zhao J, Gao M, et al. Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases. Int J Clin Oncol. 2018;23:59–65. doi: 10.1007/s10147-017-1170-6.
    1. Hung YP, Barletta JA. A user’s guide to non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) Histopathology. 2018;72:53–69. doi: 10.1111/his.13363.
    1. Amendoeira I, Maia T, Sobrinho-Simoes M. Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): impact on the reclassification of thyroid nodules. Endocr Relat Cancer. 2018;25:R247–R258. doi: 10.1530/ERC-17-0513.
    1. Sancho JJ, Lennard TW, Paunovic I, Triponez F, Sitges-Serra A. Prophylactic central neck dissection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES) Langenbeck’s Arch Surg. 2014;399:155–163. doi: 10.1007/s00423-013-1152-8.
    1. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24:27–34. doi: 10.1089/thy.2013.0367.
    1. Sugitani I, Fujimoto Y, Yamada K. Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma. World J Surg. 2014;38:673–678. doi: 10.1007/s00268-013-2335-8.
    1. Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;68:55–63. doi: 10.3322/caac.21439.
    1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. doi: 10.1089/thy.2015.0020.
    1. Xue S, Wang P, Hurst ZA, Chang YS, Chen G. Active surveillance for papillary thyroid microcarcinoma: challenges and prospects. Front Endocrinol (Lausanne) 2018;9:736. doi: 10.3389/fendo.2018.00736.
    1. Oda H, Miyauchi A, Ito Y, et al. Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery. Thyroid. 2016;26:150–155. doi: 10.1089/thy.2015.0313.
    1. Miyauchi A. Clinical trials of active surveillance of papillary microcarcinoma of the thyroid. World J Surg. 2016;40:516–522. doi: 10.1007/s00268-015-3392-y.
    1. NCCN Clinical Practice Guidelines in Oncology, 2019. Available in:
    1. Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144:1070–1077. doi: 10.1016/j.surg.2008.08.034.
    1. Park HK, Kim DW, Ha TK, et al. Factors associated with postoperative hypothyroidism after lobectomy in papillary thyroid microcarcinoma patients. Endocr Res. 2015;40:49–53. doi: 10.3109/07435800.2014.933975.
    1. Lee DY, Seok J, Jeong WJ, Ahn SH. Prediction of thyroid hormone supplementation after thyroid lobectomy. J Surg Res. 2015;193:273–278. doi: 10.1016/j.jss.2014.07.003.
    1. Woliński K, Szkudlarek M, Szczepanek-Parulska E, Ruchała M. Usefulness of different ultrasound features of malignancy in predicting the type of thyroid lesions: a meta-analysis of prospective studies. Pol Arch Med Wewn. 2014;124:97–104.
    1. Stacey D, Legare F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;1:CD001431.
    1. Hoffmann TC, Legare F, Simmons MB, et al. Shared decision making: what do clinicians need to know and why should they bother? Med J Aust. 2014;201:35–39. doi: 10.5694/mja14.00002.
    1. Sivanandan R, Soo KC. Pattern of cervical lymph node metastases from papillary carcinoma of the thyroid. Br J Surg. 2001;88:1241–1244. doi: 10.1046/j.0007-1323.2001.01843.x.
    1. Gur EO, Karaisli S, Haciyanli S, et al. Multifocality related factors in papillary thyroid carcinoma. Asian J Surg. 2019;42:297–302. doi: 10.1016/j.asjsur.2018.05.004.
    1. Mirallie E, Visset J, Sagan C, et al. Localization of cervical node metastasis of papillary thyroid carcinoma. World J Surg. 1999;23:970–973. doi: 10.1007/s002689900609.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever